Group 1 - RAYS Capital Partners Limited increased its stake in Baixinan-B (02185) by purchasing 800,000 shares at a price of HKD 8.749 per share, totaling HKD 6.9992 million [1] - After the acquisition, RAYS Capital's total shareholding in Baixinan-B reached 11.8682 million shares, representing a 5.03% ownership stake [1]

（原标题：RAYS Capital Partners Limited增持百心安-B(02185)80万股 每股作价8.749港元） 智通财经APP获悉，香港联交所最新资料显示，10月17日，RAYS Capital Partners Limited增持百心安- B(02185)80万股，每股作价8.749港元，总金额为699.92万港元。增持后最新持股数目为1186.82万股， 最新持股比例为5.03%。 ...

Group 1: Market Overview - The Hang Seng Index fell by 0.43%, down 111 points, closing at 25,799 points, while the Hang Seng Tech Index dropped by 1.36% [1] - The Hong Kong stock market saw a trading volume of HKD 156.2 billion in the morning session [1] Group 2: Biotechnology and Pharmaceuticals - HEC Pharm (02617) experienced a short-term surge, rising by 42% with a trading volume exceeding HKD 1.1 billion [1] - Rongchang Bio (09995) rose over 5% following the publication of its Phase III clinical trial results for Taitasip in treating systemic lupus erythematosus in NEJM [2] - Baixin An-B (02185) increased by over 10%, with institutions indicating that its commercialization is set to accelerate [5] Group 3: Telecommunications and Technology - ZTE Corporation (00763) saw a peak increase of 7%, with its stock price up over 80% year-to-date, as the company strengthens its research and development in intelligent computing products [3] Group 4: Aviation Sector - Major airlines in Hong Kong reported strong operational data for September, indicating a potential sustained recovery in the industry, with China Eastern Airlines (00670) up 4.9% and China Southern Airlines (01055) up 2% [3] Group 5: Consumer Sector - New consumption concept stocks in Hong Kong collectively rose, with Lao Pu Gold (06181) up 6%, Wei Long (09985) up 3%, Pop Mart (09992) up over 5%, and Guoquan (02517) up over 3% [3] Group 6: Education Sector - Education stocks in Hong Kong surged, with Think Tank Education (01769) leading with an increase of over 18%, and New Oriental-S (09901) rising over 6% [4] Group 7: Energy Sector - COSCO Shipping Energy (01138) rose over 4% due to strong demand in the crude oil tanker market in September, with VLCC freight rates expected to strengthen [6] Group 8: Market Volatility - Bit Strategy (06113) fell over 9% after being named by the Hong Kong Securities and Futures Commission for having highly concentrated shareholding [7] - Xiaomi Group-W (01810) declined by 3%, with institutions noting that its stock price volatility is influenced by multiple news events and market rumors [8]

每经AI快讯，百心安-B(02185.HK)涨超10%，截至发稿，涨13.5%，报8.83港元，成交额1.06亿港元。 ...

Core Viewpoint - The stock of Baixinan-B (02185) has seen a significant increase, with a rise of over 14% during trading, currently reported at 8.70 HKD, with a trading volume of 109 million HKD. This surge is attributed to positive developments in the renal denervation (RDN) market, particularly following Boston Scientific's acquisition of SoniVie for 600 million USD and updates to hypertension treatment guidelines by major American health organizations [1]. Company Summary - Baixinan's Iberis RDN system is the only globally approved device that offers both transradial (TRA) and transfemoral access for RDN, providing a significant first-mover advantage in the market [1]. - The company has established strategic partnerships with Yuan Da Health and other international entities, which are expected to accelerate its commercialization efforts [1]. Industry Summary - The RDN procedure is emerging as a new therapeutic approach for uncontrolled and resistant hypertension, with a projected market size in China exceeding 10 billion RMB by 2032, according to Frost & Sullivan [1]. - Recent updates from the American College of Cardiology and the American Heart Association have included RDN in their IIb level recommendations for hypertension treatment, indicating a growing acceptance and potential for clinical application [1]. - The proposed national coverage decision by the Centers for Medicare & Medicaid Services (CMS) in the U.S. is expected to significantly expedite the clinical promotion and application of RDN if approved [1].

Core Viewpoint - Baixinan-B (02185) has seen a significant increase of over 10%, currently up 13.5% at HKD 8.83, with a trading volume of HKD 106 million [1] Group 1: Market Developments - Boston Scientific is set to acquire SoniVie for a total price of USD 600 million by March 2025, indicating a strong entry into the RDN market [1] - The American College of Cardiology and the American Heart Association updated hypertension treatment guidelines in August, incorporating RDN as a Class IIb recommendation [1] - The proposed national coverage decision for RDN by the Centers for Medicare & Medicaid Services (CMS) in July, if approved, will significantly accelerate clinical adoption [1] Group 2: Industry Insights - Percutaneous renal denervation (RDN) is a new therapeutic device for uncontrolled and resistant hypertension [1] - According to Frost & Sullivan, the market size for RDN in China is expected to exceed RMB 10 billion by 2032 [1] - Baixinan's Iberis RDN system is the only globally approved device that can perform RDN via both transradial (TRA) and transfemoral approaches, providing a significant first-mover advantage [1] Group 3: Strategic Partnerships - Baixinan has established significant strategic partnerships with Yuan Da Health and various countries for commercial acceleration [1] - The Iberis RDN system has been included in health insurance coverage in Germany and France, further supporting Baixinan's commercialization efforts [1]

Core Viewpoint - Baixinan-B (02185) has seen a significant stock price increase of over 10%, currently up 13.5% at HKD 8.83, with a trading volume of HKD 106 million [1] Group 1: Market Developments - Boston Scientific is set to acquire SoniVie for a total price of USD 600 million, actively entering the RDN (Renal Denervation) market by March 2025 [1] - The American College of Cardiology and the American Heart Association updated hypertension treatment guidelines in August, incorporating RDN as a Class IIb recommendation [1] - The Centers for Medicare & Medicaid Services (CMS) proposed a national coverage decision for RDN in July, which, if approved, will significantly accelerate clinical adoption [1] Group 2: Industry Insights - RDN is a new therapeutic device for uncontrolled and resistant hypertension, with the Chinese RDN market expected to exceed RMB 10 billion by 2032 according to Zhi Shi Consulting [1] - Baixinan's Iberis RDN system is the only globally approved device that offers both transradial (TRA) and transfemoral access for RDN, providing a significant first-mover advantage [1] - Strategic partnerships have been established with Yuan Da Health and other international companies to accelerate commercialization, with Germany and France already including Iberis RDN in their healthcare coverage [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海百心安生物技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02185 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 235,703,422 | RMB | | | 1 RMB | | 235,703,422 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 235,703,422 | RMB | | | 1 RMB | | ...

Core Viewpoint - Baixinan-B (02185) has seen a nearly 10% increase in stock price, currently trading at 7.85 HKD, with a transaction volume of 11.7587 million HKD, following a strategic partnership announcement with Bluestar Medical (002382) for the Iberis RDN system [1] Company Summary - Baixinan has established a "going abroad" cooperation with Bluestar Medical, leveraging its platform capabilities and industry reputation [1] - The Iberis RDN system has achieved commercialization in countries such as Germany, Spain, and Italy, with Germany and France including it in their healthcare insurance [1] - The Iberis RDN system is the only one globally approved for both transradial (TRA) and transfemoral access routes, providing a significant first-mover advantage [1] Industry Summary - Percutaneous renal denervation (RDN) is a new therapeutic device for uncontrolled and resistant hypertension [1] - According to Frost & Sullivan, the annual market size for RDN in China is expected to exceed 10 billion RMB by 2032 [1] - The inclusion of the Iberis RDN system in the healthcare insurance of Germany and France is expected to accelerate Baixinan's commercialization efforts [1]

2025 中報 2025 Interim Report 目錄 | 2 | 公司資料 | | --- | --- | | 4 | 財務摘要 | | 5 | 管理層討論及分析 | | 16 | 其他資料 | | 26 | 中期簡明綜合損益及其他全面收益表 | | 27 | 中期簡明綜合財務狀況表 | | 29 | 中期簡明綜合權益變動表 | | 30 | 中期簡明綜合現金流量表 | | 32 | 中期簡明綜合財務資料附註 | | 45 | 釋義 | 1 上海百心安生物技術股份有限公司 二零二四年年報 公司資料 董事會 執行董事 汪立先生 （董事長、首席執行官兼總經理） 王雲磬先生 （首席財務官、董事會秘書兼聯席公司秘書） 王佩麗女士 獨立非執行董事 陳軼青先生 魯旭波先生 蔣一斐先生 審核委員會 陳軼青先生 （主席） 魯旭波先生 蔣一斐先生 薪酬委員會 魯旭波先生 （主席） 陳軼青先生 蔣一斐先生 提名委員會 蔣一斐先生 （主席） 魯旭波先生 王佩麗女士 （於2025年3月28日任命） 汪立先生 （2025年3月28日起不再擔任成員） 監事 蔡濤先生 （主席） 朱磊先生 王君毅先生 聯席公司秘書 王雲磬先生 郭兆 ...